Overexpression of LAPTM4B-35 is associated with poor prognosis in colorectal carcinoma

Kang, Yue; Yin, Mingzhu; Jiang, Wei; Zhang, Haiyu; Xia, Bairong; Xue, Yingwei; Huang, Yuenan

doi:10.1016/j.amjsurg.2012.02.003

Cited by 32 publications

(23 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LAPTM4B is closely related with the biological behaviors of malignant tumors. An increase in LAPTM4B expression, as measured by mRNA and protein, was associated with tumor progression and poorer survival in patients with breast (25), pancreatic (8), colon (26), ovary (27) and cervical cancer (11). Furthermore, extensive studies have been performed to account for such outcomes.…”

Section: Discussionmentioning

confidence: 99%

LAPTM4B polymorphism is associated with non-small cell lung cancer susceptibility and prognosis

et al. 2014

View full text Add to dashboard Cite

Abstract. Lysosome-associated protein transmembrane-4β (LAPTM4B) is a novel cancer-related gene that is upregulated in many tumors, and which plays important roles in carcinogenesis. It has two alleles, LAPTM4B*1 and LAPTM4B*2. LAPTM4B*1 contains only one copy of a 19-bp sequence in the first exon, whereas LAPTM4B*2 contains two tight tandem segments. Previous studies have shown that LAPTM4B*2 is a risk factor for susceptibility and prognosis of many tumors. The present study investigated the relationship between LAPTM4B polymorphism and non-small cell lung cancer (NSCLC) susceptibility and prognosis. We identified LAPTM4B genotypes with polymerase chain reaction (PCR) in peripheral blood samples. In the adjusted multivariate logistic regression analysis, we found that LAPTM4B*1/2, LAPTM4B*2/2 exhibited 1.48-fold [95% confidence interval (CI), 1.076-2.037] and 2.855-fold (95%CI, 1.722-4.734) increases in the risk of developing NSCLC compared with non-LAPTM4B*2 carriers. Furthermore, our results showed that overall survival time and disease-free survival time of patients with LAPTM4B*2 were significantly shorter than in patients carrying LAPTM4B*1 (P=0.001 and P=0.001, respectively). In addition, multivariate Cox regression analysis revealed that LAPTM4B*2 was also an independent prognostic factor for NSCLC. These results suggest that LAPTM4B polymorphisms may be a prospective marker for evaluating the risk and prognosis of NSCLC.

show abstract

Section: Discussionmentioning

confidence: 99%

LAPTM4B polymorphism is associated with non-small cell lung cancer susceptibility and prognosis

et al. 2014

View full text Add to dashboard Cite

show abstract

“…In tumors, it appears to play an oncogenic role. High LAPTM4B levels are associated with poor prognosis in many types of cancers (31)(32)(33)(34)(35)(36)(37)(38)(39)(40)(41), and in vitro and in vivo analyses of cells in which LAPTM4B was overexpressed or silenced indicate that LAPTM4B favors proliferation, migration, invasion, tumorigenesis, and metastasis (42,43). Two mechanisms by which LAPTM4B plays oncogenic roles have recently been identified.…”

Section: Discussionmentioning

confidence: 99%

Lysosomal-associated Transmembrane Protein 4B (LAPTM4B) Decreases Transforming Growth Factor β1 (TGF-β1) Production in Human Regulatory T Cells

Huygens¹,

Liénart²,

Dedobbeleer³

et al. 2015

Journal of Biological Chemistry

View full text Add to dashboard Cite

Background: TGF-␤1 produced by regulatory T lymphocytes suppresses excessive immune responses. Results: Lysosomal-associated transmembrane protein 4B (LAPTM4B) was found to inhibit TGF-␤1 production in Tregs. Conclusion: LAPTM4B, known to exert oncogenic functions in tumor cells, also plays a role in the immune system. Significance: LAPTM4B may represent a new therapeutic target to modulate immunosuppression by Tregs.

show abstract

“…3 Besides, a series of clinical experiments showed that carcinomas derived from stomach, breast, colon, ovary, liver, pancreas, cervix, prostate, lung, endomentrium and gallbladder with LAPTM4B-35 overexpression may present more invasive characteristics. 10, 36, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 …”

Section: Functions Of Laptm4b and The Mechanisms Thereofmentioning

confidence: 99%

LAPTM4B: an oncogene in various solid tumors and its functions

Zhang

Wang

et al. 2016

Oncogene

View full text Add to dashboard Cite

The oncogene Lysosome-associated protein transmembrane-4β (LAPTM4B) gene was identified, and the polymorphism region in the 5′-UTR of this gene was certified to be associated with tumor susceptibility. LAPTM4B-35 protein was found to be highly expressed in various solid tumors and could be a poor prognosis marker. The functions of LAPTM4B in solid tumors were also explored. It is suggested that LAPTM4B could promote the proliferation of tumor cells, boost invasion and metastasis, resist apoptosis, initiate autophagy and assist drug resistance.

show abstract

Overexpression of LAPTM4B-35 is associated with poor prognosis in colorectal carcinoma

Cited by 32 publications

References 21 publications

LAPTM4B polymorphism is associated with non-small cell lung cancer susceptibility and prognosis

LAPTM4B polymorphism is associated with non-small cell lung cancer susceptibility and prognosis

Lysosomal-associated Transmembrane Protein 4B (LAPTM4B) Decreases Transforming Growth Factor β1 (TGF-β1) Production in Human Regulatory T Cells

LAPTM4B: an oncogene in various solid tumors and its functions

Contact Info

Product

Resources

About